Prime setup for $ARKG as we hit the midway point of Bloody September, the worst month for returns. We've already seen several pullbacks, and with quad witching coming on Sept 17, we're bound to see some volatility.
I fully expect ARKG to fall a little further as the broader market bleeds, but come the quad witching hour, you'll start to see the tides shifting....
Hello dear padawans. Short and sweet analysis on Invitae:
$NVTA on long term support. It is also oversold. Given the lower shadow of current candle investors have strong appetite for current prices
On the flip side one could venture reading the long term formation as a head and shoulders pattern.
If you are a long term investor, buying here is a no brainer...
It looks like wave 2 has not completed yet. If we get a bounce and rejection off of the DTL and PoC line, and break the support around 82, we could see a completion of wave 2 around 75-76 followed by wave 3 to 110+
these four are signficant players in the genome sequencing market, but RHHB stock price hasn't take off in the same way, and Agilent is way out in front.
Does this make RHHB a good buy, or, is there something wrong, and making the others a better prospect? Is Agilent a sell?
This play looks tempting ngl. NASDAQ:BNGO
Bionanon made very tasty returns so why not return. Price is near 0+/- ATR in keltner and if it closes above I will enter.
Last time I entered around $5 and avg'ED up till $5.6.
Took Profit around $14 but this chart looks promising.
Genomics is still an underrated sector and there are many supporters of its hot...
ARKG looks like a double bounce at the bottom of thee channel, which is also the 0.382 retracement of the wave 4. Probably a little bit more channeling here before we get going.
If we get a reversal here, wave 5 should bring us to anywhere between 145-160 by EoY
Here is my follow up update on original CRSP swing short trade idea I put up on January 14th.
On this post, I am zooming out to weekly chart, looking at longer time frame to capture cyclical trends.
Going back all the way to 2017 inception period, the higher than average volatilities are pretty easy to notice. It moves up really fast but also coming down. Every...
EDIT NASDAQ:EDIT is a genome editing company with treatments being developed for Leber congenital amaurosis**, Usher syndrome, neurological diseases, Sickle cell disease, beta-thalassemia, as well as cancer treatments through NK cells. The leber congenital amaurosis clinical trial is currently the furthest along but still in its earlier stages but has completed...
The short volume ratio is decreasing which means good news for us. - Fintel
Also looks like it's time for a reversal on the 1HR MACD so we could be in for a breakout with a high upside. All I'm hearing is nothing but good news associated with Bionano Genomics.
However, we cannot fail to ignore the declining revenues every year. Keep an eye on this till the next...
Since early December, we have had over a dozen tails on the purple up-trend arrow drawn in.
The 50sma is now coming into play, as a break below that, could take us another 20% down to the 100sma.
An appropriate level to exit the trade then, would be below the 50sma.
There also horizontal support as we fill the gap.